Verition Fund Management
REGN icon

Verition Fund Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Verition Fund Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.18M Buy
+6,700
New +$5.13M 0.03% 564
2025
Q4 		– Sell
-500
Closed -$281K – 3868
2025
Q3 		$281K Hold
500
– – ﹤0.01% 3329
2025
Q2 		$263K Buy
+500
New +$279K ﹤0.01% 3260
2025
Q1 		– Sell
-900
Closed -$641K – 3652
2024
Q4 		$641K Sell
900
-6,100
-87% -$5.12M ﹤0.01% 2328
2024
Q3 		$7.36M Hold
7,000
– – 0.04% 582
2024
Q2 		$7.36M Hold
7,000
– – 0.04% 508
2024
Q1 		$6.74M Buy
7,000
+4,100
+141% +$3.9M 0.05% 506
2023
Q4 		$2.55M Buy
2,900
+2,600
+867% +$2.14M 0.02% 724
2023
Q3 		$247K Sell
300
-800
-73% -$629K ﹤0.01% 1849
2023
Q2 		$790K Buy
+1,100
New +$848K 0.01% 1011
2023
Q1 		– Sell
-5,100
Closed -$3.68M – 2489
2022
Q4 		$3.68M Sell
5,100
-300
-6% -$221K 0.06% 417
2022
Q3 		$3.72M Buy
+5,400
New +$3.4M 0.04% 565
2022
Q2 		– Sell
-6,400
Closed -$4.47M – 2935
2022
Q1 		$4.47M Buy
6,400
+1,000
+19% +$633K 0.05% 442
2021
Q4 		$3.41M Buy
+5,400
New +$3.32M 0.02% 550

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Verition Fund Management's REGN Position: Q1 2026 in Review

Verition Fund Management reduced its Regeneron Pharmaceuticals (REGN) stake by 84% in Q1 2026, selling an estimated $6.13M and leaving 1,478 shares worth $1.14M. The position accounts for 0.01% of the portfolio, ranked #1254.

Verition Fund Management first reported a position in REGN in Q2 2013 and has held it in 42 quarters since. The position peaked at $18.7M in Q4 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Verition Fund Management held 1,478 shares of Regeneron Pharmaceuticals worth $1.14M as of Q1 2026.
  • Verition Fund Management sold 8,013 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $6.13M.
  • Regeneron Pharmaceuticals made up 0.01% of Verition Fund Management's portfolio in Q1 2026, its #1254 holding.
  • Verition Fund Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
  • Verition Fund Management's Regeneron Pharmaceuticals position peaked at $18.7M in Q4 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.